FDA committee recommends approval of Keytruda in high-risk NMIBC

This article was originally published here

The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 9-4 in favour of approving Keytruda for the new indication. The anti-PD-1 therapy has already been approved in the US

The post FDA committee recommends approval of Keytruda in high-risk NMIBC appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply